TREATMENT WITH ANTI-TIGIT ANTIBODIES AND PD-1 AXIS BINDING ANTAGONISTS

The present invention relates to the treatment of esophageal cancer, e.g., esophageal squamous cell carcinoma (ESCC) (e.g., advanced ESCC (e.g., unresectable, locally advanced, recurrent, and/or metastatic ESCC)). More specifically, the invention pertains to the treatment of patients having esophage...

Full description

Saved in:
Bibliographic Details
Main Authors CHA, Edward Namserk, HARRIS, Meghna Das Thakur, GE, Feijiao, LI, Shi, WANG, Yifan
Format Patent
LanguageEnglish
Published 23.12.2021
Subjects
CHEMISTRY
ELECTROTHERAPY
HUMAN NECESSITIES
HYGIENE
MAGNETOTHERAPY
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
RADIATION THERAPY
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
ULTRASOUND THERAPY
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to the treatment of esophageal cancer, e.g., esophageal squamous cell carcinoma (ESCC) (e.g., advanced ESCC (e.g., unresectable, locally advanced, recurrent, and/or metastatic ESCC)). More specifically, the invention pertains to the treatment of patients having esophageal cancer by administering a combination of an anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) antagonist antibody and a programmed death-1 (PD-1) axis binding antagonist.
Bibliography:Application Number: US202117159063